American biopharma giant
The FDA has approved daraxonrasib, sold as Rasonque by Revolution Medicines, for adults with previously treated or ineligible metastatic pancreatic cancer. Clinical trials have shown median survival extended to about 13.2 months versus roughly 6.7 months with chemotherapy. The drug will be available in the US with a roughly $39,800 monthly list price and expanded-access programmes have already treated thousands.
Late-stage trials show sacituzumab tirumotecan improves median overall survival to 19 months versus 12.1 months with chemotherapy, but with notable side effects. New ovarian cancer therapy rinatabart sesutecan also demonstrates a strong progression-free survival benefit. Other programs in the field report positive results, signaling a robust biotech landscape but with continued safety concerns.